Michael J. Welch Award
Henry VanBrocklin, PhD
Reinier Hernandez, PhD
Michael J. Welch Postdoctoral Travel Grant
Zhen Yang, PhD
Marc Tetalman, MD Memorial Award
Ali Salavati, MD, MPH
Marta Cremonesi, PhD
Ursula Mary Kocemba-Slosky, PhD Professional Relations Fellowship
Lucas Gross, CNMT
Robert E. Henkin, MD, Government Relations Fellowship
Jusitn Peacock, MD, PhD
Mitzi & William Blahd, MD, Pilot Research Grant
Mark Dornan, PhD
ERF SNMMI CMIIT Laboratory Professional Recognition Award for Contributions to Molecular Imaging
Bradley-Alavi Student Fellowships
Paul C. Aebersold, PhD Award
Carolyn Anderson, PhD
ERF SNMMI Medical Science Student Research Grant
Susan C. Weiss Clinical Advancement Scholarship
ERF SNMMI-TS Bachelor’s or Master’s degree Completion Scholarship
ERF SNMMI-TS Advanced Degree Scholarship
Mary Beth Farrell
SNMMI-TS/ERF Outstanding Technologist
Matthew C. McMahon, MS, CNMT, RT(CT)
SNMMI-TS/ERF Outstanding Educator
Geoffrey M. Currie, PhD BPharm MMRS CNMT
ERF SNMMI Journal of Nuclear Medicine Best Paper
Journal of Nuclear Medicine Technologist Best PaperSarah Frye
Audrey B. Davis
Paul Cole Technologist Scholarship
Jean Pierre Alfonso
2020 ERF-SNMMI Young Investigator Awards
Nele Inga Hermanns
Martin Lyngby Lassen
Rocio Garcia Vazquez
Diane S. Abou
Reinier Hernandez, PhD
Technologist Best Oral Abstract
Technologist Best Poster Award
to predict progression free and overall survival after peptide receptor radionuclide
therapy: a multivariate analysis in 782 patients
experience of rechallenge 177Lu-PSMA radioligand therapy after an
initial good response in patients with mCRPC
a semi-automatic software for whole-body tumor burden assessment in prostate
cancer using 68Ga-PSMA11 PET/CT
prospective observational study to evaluate the effects of long-acting
somatostatin analogs on 68Ga-DOTATATE uptake in patients with
and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for
Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor
Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-
11C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and Tightrope
Walk between GluN2B- and Sigma1 Receptor-Targeted PET Imaging
Evaluation of 111In-labeled PEGylated Maytansine Nimotuzumab Drug
Conjugates in EGFR-positive Cancer Models
lysis syndrome: a rare, but serious complication of radioligand therapies
of PET attenuation map for whole-body time-of-flight 18F-FDG PET/MRI
using a deep neural network trained with simultaneously reconstructed activity and
FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic
Tissue Uptake of 68Ga-Prostate Specific Membrane Antigen (PSMA), 18F-DCFPyL,
18F-Fluoromethylcholine (FCH) and 18F-Dihydrotestosterone
Methods for Quantification of 18F-DCFPyL Uptake in Patients with
towards a non-invasive clinical tool to measure target engagement of
therapeutic antibodies in-vivo
tumor perfusion imaging with 82Rubidium-PET/CT in prostate cancer -;
analytical and clinical validation
of Cerenkov-assisted Photoactivation of TiO2 Nanoparticles and
Reactive Oxygen Species Generation for Cancer Treatment
PSMA Ligands: Implications for Expanding the Therapeutic Window
Glucagon Like Peptide-1 Receptors in the Exocrine Pancreas Improves Specificity
for Beta Cells in a Mouse Model of Type 1 Diabetes
a new cholecystokinin-2 receptor targeting peptide analog with optimized
targeting profile for theranostic use
of simplified methods for quantification of 18F-FDHT uptake in
patients with metastatic castration-resistant prostate cancer
Positron Emission Tomography Imaging of Activating Estrogen Receptor Alpha
Mutations in Breast Cancer
18F-labeling and preclinical evaluation of prostate specific
membrane antigen trifluoroborate probes for cancer imaging.
delayed imaging improves assessment of coronary 18F-sodium fluoride
gross patient motion detection and compensation: Implications for coronary 18F-NaF
Martin Lyngby Lassen
68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute
evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate
PET/CT for imaging of chemokine receptor-4 expression in Waldenstrom macroglobulinemia/lymphoplasmacytic
lymphoma: comparison to 18F-FDG PET/CT
vitro and in vivo characterization of a 18F-AlF-labeled PSMA ligand
for imaging of PSMA-expressing xenografts
pharmacokinetics and dosimetry studies of [124I/131I]-CLR1404
for treatment of pediatric solid tumors in murine xenograft models
effects of CXC-chemokine receptor 4 -; directed Endoradiotherapy with
Pentixather prior to Hematopoietic Stem Cell Transplantation
chemotherapy induced acute cardiotoxicity with 18F-labelled lipophilic cations
dimensional tumor-margin demarcation using the hybrid tracer indocyanine green-99mTc-nanocolloid,
a proof of concept study in tongue cancer patients scheduled for sentinel node
of a novel elastic respiratory motion correction algorithm on quantification
and image quality in abdomino-thoracic PET/CT
Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
PET imaging of memantine-induced brain activation and test-retest in freely
metabolic changes related to freezing of gait in Parkinson's disease
chain amino acids: structure-activity relationships and PET imaging potential
feature extraction for radiomics analysis of 18F-FDG-PET imaging
of a novel PET radioligand to image O-GlcNAcase in brain and periphery of
rhesus monkey and knock-out mouse.
Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and
Pretargeted Molecular Imaging of Gastric Tumors
dosimetry and biodistribution of 18F-PSMA-11 for PET imaging of
A Novel Molecular Probe for High-Contrast PET Imaging of Malignant Melanoma
of 15O for medical applications via the 16O - 15O
estimate and initial clinical experience with 90Y-PSMA-617.
versus standard imaging for prediction of survival in patients with recurrent
head and neck squamous cell carcinoma
optoacoustic tomography of benign and malignant thyroid disorders - a pilot
PET Monitoring of Amyloidosis and Microglial Activation in a Second Generation
Amyloid-beta Mouse Model
and Isoform Specificity of 18F-Fluorofuranylnorprogesterone for
Measuring Progesterone Receptor Protein Response to Estradiol Challenge in
of 68Ga-PSMA-PET/CT on the radiotherapeutic approach for prostate
cancer in comparison to CT -; a retrospective analysis
after PSMA PET/CT based salvage radiotherapy in patients with biochemical
recurrence after radical prostatectomy: a bi-institutional retrospective
imaging biomarkers for Yttrium-90 distribution on Bremsstrahlung single photon
emission computed tomography after resin-based radioembolization
11C-PiB PET shows
cerebrospinal fluid flow alterations in Alzheimer’s disease and multiple
to treat analysis of 68Ga-PSMA and 11C-choline PET/CT
versus CT for prostate cancer recurrences after surgery
effects of radioiodine treatment on salivary gland function in adult survivors
of pediatric differentiated thyroid carcinoma
Positron Emission Tomography Imaging of SHARPIN-Regulated Integrin Activity in
of 18F-PSMA-1007 uptake in prostate cancer using different peptide
concentrations: preclinical PET/CT study in mice.
of patient-specific transmission image for PET attenuation correction for
PET/MR imaging of the brain using a convolutional neural network
automatic technique for precise localization and quantification of Amyloid-β PET
Deep Learning (DIVIDE) Pseudo-CT Synthesis for Pelvis PET/MR Attenuation
FDG-PET response-assessment method best predicts survival after curative-intent
chemoradiation in non-small cell lung cancer (NSCLC): EORTC, PERCIST, Peter Mac
or Deauville criteria?
of 18F-FDG PET/CT in predicting residual
disease after neoadjuvant chemoradiotherapy for esophageal cancer
subtyping of pheochromocytoma and paraganglioma by 18F -FDG
pharmacokinetics using dynamic PET/CT scanning
Anouk van Berkel
study on hepatobiliary scintigraphy to monitor regional liver fucntion in
Sandra van der Velden
Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer
Stan van Keulen
characteristics of the digital Biograph Vision PET/CT system
Joyce van Sluis
imaging of fibroblast activity after myocardial infarction using a 68Ga-labelled
fibroblast activation protein inhibitor FAPI-04
Impact of FcγRI Binding on ImmunoPET
Effect of a Mesothelin Targeted Thorium-227 Conjugate in Combination with DNA
Damage Response Inhibitors in Ovarian Cancer Xenograft Models
imaging of PARP expression using [18F]olaparib
imaging using radiolabelled matrix metalloproteinase-activated anthrax proteins
2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of
tissues of origin
tumor detection and radiation dosimetry of F-18 5-Fluoro-2'-Deoxycytidine (18F-FdCyd)
with Tetrahydrouridine in solid tumors
Targeted Radionuclide Therapy through the National Cancer Institute’s
Small Business Innovation Research Pathway
Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and
Survival Analysis in 69 Patients
radioligand therapy in metastatic castration-resistant prostate cancer patients
with a single functioning kidney
and repeatability of quantitative uptake metrics in [18F]FDG PET/CT
imaging of non-small cell lung cancer: impact of segmentation method, uptake
interval, and reconstruction protocol
The Benedict Cassen Prize is awarded in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science. The prize award is $25,000 and is only offered every other year (even years).
This prestigious prize is named in honor of the late physicist Benedict Cassen, whose invention, the rectilinear scanner, first brought the ability to image patients to nuclear medicine. His widow, Mary Wylie Cassen, made a bequest to the Foundation to establish a major award. The awarding of this prize is in recognition of outstanding achievement is essential to encourage development and growth in nuclear medicine.
1994 - Hal O. Anger, B.S., D.Sc. (Hon.), for his invention of the scintillation camera.
1996 - David E. Kuhl, M.D., for his development of emission reconstruction tomography and quantitative measurements of brain physiology.
1998 - Henry N. Wagner, Jr., M.D., for his many contributions to Nuclear Medicine as a scientist, teacher and clinician.
2000 - Sally J. DeNardo, M.D., and Gerald L. DeNardo, M.D., for their fundamental contributions to present and future medical care through work in developing radiolabelled antibodies and contributions to the radioimmunotherapy of cancer.
2002 - Michael E. Phelps, PhD., for his exceptional involvement and work to translate PET science into clinical medical practice.
2004 - Michael J. Welch, PhD., for his work on rapid synthesis of positron-labeled organic chemicals which were of vital importance in the application of PET technology’s application to diagnostic medicine.
2006 - Alexander Gottschalk, M.D., for his pioneer work in the clinical applications of the Anger gamma camera and the use of Technetium radiotracers.
2008 - Mathew Thakur, PhD., for his original and major advances in the development of novel radiopharmaceuticals that have led nuclear medicine to play a major role in the management of patients with infections, vascular thromboembolism, and cancer.
2010 - Sung-Cheng (Henry) Huang, D.Sc., for his scholarship in applying biomathematics to the development & application of tracer kinetic models used as imaging assays of biological process in vivo with PET, from basic to clinical sciences.
2012 - Abass Alavi, MD, MD(Hon), PhD(Hon), DSc(Hon), for his contributions to the development of modern imaging techniques including Positron Emission Tomography, as revolutionary tools for conducting basic science research and improving patient care.
2012 - Steven M. Larson, M.D., for his research and leadership that have advanced nuclear medicine science, especially in uses of radionuclides for diagnosis and treatment of cancer.
2014 - Barry A. Siegel, M.D., for his sustained contributions to clinical translation of nuclear medicine science and, in particular, his visionary leadership in developing scientific methodology for evidence-based clinical trials that resulted in widespread acceptance of imaging studies using positron emission tomography.
2016 - H. William Strauss, M.D., in recognition of his seminal studies in cardiovascular nuclear medicine. These studies have greatly advanced nuclear medicine science and have had exceptionally high clinical impact.
2018 - Sanjiv Sam Gambhir, M.D., Ph.D., in recognition of his visionary leadership and rigorous science in developing and translating strategies for the imaging of human diseases using novel multimodality reporter genes and imaging agents.
2020 - Peter S. Conti, MD, PhD, in recognition of his pioneering work in the development of novel radiopharmaceuticals and clinical PET applications for cancer imaging, as well as his volunteerism and service to the molecular imaging community.
This grant was established by the Estates of Benedict Cassen and Mary Wiley Balfour Cassen to provide early-career scientists with mentoring experience and the opportunity to develop preliminary data for federal or other competitive research support. The grant will provide support for the postdoctoral fellow to carry out the research under the supervision of the junior faculty member with the assistance of a senior faculty member or principal investigator.
2014 - Marc David Normandin, PhD, Instructor of Radiology, Harvard Medical School Assistant in Physics, Massachusetts General Hospital, Department of Radiology.
Georges El Fakhri, PhD, DABR, Director, Center for Advanced Medical Imaging Sciences (CAMIS), Co-Director, Division of Nuclear Medicine & Molecular Imaging, Professor of Radiology Harvard Medical School is Dr. Normandin’s advisor.
2015 - Kyle Lapidus, MD, PhD, Assistant Professor, Director of Neuromodulation, Stony Brook University, Department of Psychiatry.
Ramin Parsey, MD, PhD, Professor and Chair of the Department of Psychiatry, Director of PET Research, Stoney Brook School of Medicine, is advisor to Dr. Lapidus.
2018 - Amy M. Fowler, M.D., Ph.D., University of Wisconsin, School of Medicine and Public Health, Department of Radiology, Breast Imaging Section
Jamey Weichert, PhD, Associate Professor in the Department of Radiology and Director of the UW-Madison Contrast Agent Laboratory is Dr. Fowler's advisor.
2016 Thomas A. Hope, MD, for "Intra-Arterial Peptide Receptor Radionuclide Therapy (IA-PRRT) using 90Y-DOTA-TOC."
2017 Babak Behnam Azad, PhD, for “An improved approach for detection and therapeutic monitoring of neuroendocrine tumors by PET.”
2018 Tara E. Mastren, PhD, for “Functionalized Silica Nanoparticles: Development of a Combined PET and TAT Theranostic Agent for Neuroendocrine Tumors.”
2019 Susanne Kossatz, PhD, for “Uncovering the cellular mechanisms that limit clinical application of PRRT.”
Monica Vilche for “68Ga-NOTA-UBI 29-41: A specific radiopharmaceutical for diagnosis of bacterial infection by PET/CT in hip prosthesis.”
Heather Jacene for“Imaging Androgen Receptors in Breast Cancer with 18F-fluoro-5α-dihydrotestosterone-PET: A Pilot Study”